Do You Want To Be Part Of The ASGCT 2023 Gene Therapy Curriculum?
ASGCT (American Society of Gene and Cell Therapy) and NORD (National Organization for Rare Disorders) has partnered exclusively with PlatformQ Health to produce accredited gene and cell therapy education with top specialist experts. Together, the companies will deliver continuing medical education for clinicians as well as educational programs for patients and their families.
“This strategic partnership is crucial for helping providers and patients make the most of their understanding of emerging therapies,” said PlatformQ Health CEO Robert Rosenbloom. “It is extremely gratifying to partner with a deeply committed professional membership society such as the American Society of Gene & Cell Therapy to deliver education about life-altering new therapies.”
Target Provider Participants Will Include:
- Primary care physicians (IMs/FPs/GPs, OB/GYNs)
- Genetic counselors
- Payers/Health Systems
- Other aligned HCPs in care of patient on Gene & Cell Therapy
Reaching Targeted Participants Through Microlearning
In addition, with your support of this program, we will develop four non-accredited microlearning videos with highly targeted content presented by KOLs that addresses gene and/or cell therapy in relevant disease states.
Through a unique partnership with IQVIA, these four videos (2-4 minutes each) will be distributed via LinkedIn to targeted physicians. PQHE will report
Past experience in Gene Therapy Education
Our 2020-2021 inaugural Gene Therapy Congress drew almost 2,000 learners and resulted in this publication of our educational outcomes at the 2022 ASGCT Gene Therapy Congress. See a sample of last year’s program here.
Industry-leading approach to outcomes: Respected as industry leader in CME and patient education outcomes reporting. We show outcomes at different times throughout the program each including select participation, demographic, and engagement metrics.
- At-a-glance (45 days post-launch)
- Interim (120 days post-launch)
- Final (60 days post-expiration)
The American Society of Gene and Cell Therapy (ASGCT) is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals in gene and cell therapy. Our mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies.
The ASGCT Patient Education program provides accurate, reliable, and accessible information about gene and cell therapies to patients and the public. ASGCT collaborates with patient advocacy groups to make sure the information is clear and useful, while members of the ASGCT Patient Outreach Committee use their expertise in the field to provide scientific accuracy.